A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis

► A novel GLP-1 gene therapy utilizing a strategy involving site-specific genome integration. ► AAVS1 locus of human chromosome 19 has been considered as a safe integration site for gene therapy. ► The plasmid-AAVS1 specific integration yields GLP-1 production in mice carrying AAVS1. ► This therapy improves metabolic status in the AAVS1 mice on high-fat diet feeding. ► This approach shows no detrimental effects and thus may find clinical applications.